Skip to main content
Top
Published in: Intensive Care Medicine 7/2022

13-05-2022 | Antibiotic | Original

Comparison of 8 versus 15 days of antibiotic therapy for Pseudomonas aeruginosa ventilator-associated pneumonia in adults: a randomized, controlled, open-label trial

Authors: Adrien Bouglé, Sophie Tuffet, Laura Federici, Marc Leone, Antoine Monsel, Thomas Dessalle, Julien Amour, Claire Dahyot-Fizelier, François Barbier, Charles-Edouard Luyt, Olivier Langeron, Bernard Cholley, Julien Pottecher, Tarik Hissem, Jean-Yves Lefrant, Benoit Veber, Matthieu Legrand, Alexandre Demoule, Pierre Kalfon, Jean-Michel Constantin, Alexandra Rousseau, Tabassome Simon, Arnaud Foucrier, the iDIAPASON Trial Investigators

Published in: Intensive Care Medicine | Issue 7/2022

Login to get access

Abstract

Purpose

Duration of antibiotic therapy for ventilator-associated pneumonia (VAP) due to non-fermenting Gram-negative bacilli (NF-GNB), including Pseudomonas aeruginosa (PA) remains uncertain. We aimed to assess the non-inferiority of a short duration of antibiotics (8 days) vs. prolonged antibiotic therapy (15 days) in VAP due to PA (PA-VAP).

Methods

We conducted a nationwide, randomized, open-labeled, multicenter, non-inferiority trial to evaluate optimal duration of antibiotic treatment in PA-VAP. Eligible patients were adults with diagnosis of PA-VAP and randomly assigned in 1:1 ratio to receive a short-duration treatment (8 days) or a long-duration treatment (15 days). A pre-specified analysis was used to assess a composite endpoint combining mortality and PA-VAP recurrence rate during hospitalization in the intensive care unit (ICU) within 90 days.

Results

The study was stopped after 24 months due to slow inclusion rate. In intention-to-treat population (n = 186), the percentage of patients who reached the composite endpoint was 25.5% (N = 25/98) in the 15-day group versus 35.2% (N = 31/88) in the 8-day group (difference 9.7%, 90% confidence interval (CI) −1.9%–21.2%). The percentage of recurrence of PA-VAP during the ICU stay was 9.2% in the 15-day group versus 17% in the 8-day group. The two groups had similar median days of mechanical ventilation, of ICU stay, number of extra pulmonary infections and acquisition of multidrug-resistant (MDR) pathogens during ICU stay.

Conclusions

Our study failed to show the non-inferiority of a short duration of antibiotics in the treatment of PA-VAP, compared to a long duration. The short duration strategy may be associated to an increase of PA-VAP recurrence. However, the lack of power limits the interpretation of this study.
Appendix
Available only for authorised users
Literature
2.
go back to reference Torres A, Niederman MS, Chastre J et al (2017) International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia: Guidelines for the management of hospital-acquired pneumonia (HAP)/ventilator-associated pneumonia (VAP) of the European Respiratory Society (ERS), European Society of Intensive Care Medicine (ESICM), European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and Asociación Latinoamericana del Tórax (ALAT). Eur Respir J. https://doi.org/10.1183/13993003.00582-2017CrossRefPubMed Torres A, Niederman MS, Chastre J et al (2017) International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia: Guidelines for the management of hospital-acquired pneumonia (HAP)/ventilator-associated pneumonia (VAP) of the European Respiratory Society (ERS), European Society of Intensive Care Medicine (ESICM), European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and Asociación Latinoamericana del Tórax (ALAT). Eur Respir J. https://​doi.​org/​10.​1183/​13993003.​00582-2017CrossRefPubMed
10.
go back to reference European Medicines Agency (2013) Addendum to the guideline on the evaluation of medicinal products indicated for treatment of bacterial infections. Committee for Human Medicinal Products European Medicines Agency (2013) Addendum to the guideline on the evaluation of medicinal products indicated for treatment of bacterial infections. Committee for Human Medicinal Products
12.
go back to reference Berry DA (1996) Statistics: a Bayesian perspective Berry DA (1996) Statistics: a Bayesian perspective
16.
go back to reference Medina J, Perez Protto S, Paciel D, Pontet J, Saldun P, Berro M (2007) Antibiotic treatment for the ventilator-associated pneumonia: 8 vs 12 days randomized trial preliminary data. In: Proceedings of the 47th interscience conference on antimicrobial agents and chemotherapy, Chicago, IL, 17–20 Sept 2007, p 361 Medina J, Perez Protto S, Paciel D, Pontet J, Saldun P, Berro M (2007) Antibiotic treatment for the ventilator-associated pneumonia: 8 vs 12 days randomized trial preliminary data. In: Proceedings of the 47th interscience conference on antimicrobial agents and chemotherapy, Chicago, IL, 17–20 Sept 2007, p 361
Metadata
Title
Comparison of 8 versus 15 days of antibiotic therapy for Pseudomonas aeruginosa ventilator-associated pneumonia in adults: a randomized, controlled, open-label trial
Authors
Adrien Bouglé
Sophie Tuffet
Laura Federici
Marc Leone
Antoine Monsel
Thomas Dessalle
Julien Amour
Claire Dahyot-Fizelier
François Barbier
Charles-Edouard Luyt
Olivier Langeron
Bernard Cholley
Julien Pottecher
Tarik Hissem
Jean-Yves Lefrant
Benoit Veber
Matthieu Legrand
Alexandre Demoule
Pierre Kalfon
Jean-Michel Constantin
Alexandra Rousseau
Tabassome Simon
Arnaud Foucrier
the iDIAPASON Trial Investigators
Publication date
13-05-2022
Publisher
Springer Berlin Heidelberg
Published in
Intensive Care Medicine / Issue 7/2022
Print ISSN: 0342-4642
Electronic ISSN: 1432-1238
DOI
https://doi.org/10.1007/s00134-022-06690-5

Other articles of this Issue 7/2022

Intensive Care Medicine 7/2022 Go to the issue

Lasting Legacy in Intensive Care Medicine

Lung recruitment